Sedation is often needed to reduce anxiety and improve comfort during anaesthetic, surgical and nursing procedures on surgical and critically ill patients. An ideal sedative agent should be inexpensive, rapid in onset and offset, and lack respiratory depression or other systemic adverse effects. So far, no single sedative agent has been proved superior to all others [1] [2] [3] and the sedative agent of choice largely depends on availability of the drug and experience of the person who is administering the sedation. Choosing an optimal sedative agent for neurosurgical patients is challenging due to a requirement to differentiate sedative effect from altered consciousness caused by underlying brain pathology. In fact, traditional teaching has advised that an intracranial pressure monitor may be required when sedation is used for a patient with significant brain injury and a computed tomography brain scan is needed if a neurosurgical patient is slow to wake from anaesthesia or sedation.
In this issue of Anaesthesia and Intensive Care, we have an interesting pilot study comparing dexmedetomidine to propofol as a sedative agent in neurosurgical patients, which concluded that they had comparable effects on the neurobiology of the brain 4 . Before we infer that dexmedetomidine is just an expensive alternative to propofol for neurosurgical patients, we have to understand the limitations of the study and the existing literature on potential benefits and risks of dexmedetomidine as a sedative agent for neuro-surgical patients. First, this pilot study assessed the neurobiological effects of propofol and dexmedetomidine only for a limited period of time (six hours). Second, many of these patients had already received propofol as a sedative drug for a period that was longer than the duration of the study prior to enrolment. Third, the washout period between the crossover assignment of either sedative agent was relatively short (two hours) compared to the terminal half-life of dexmedetomidine (3.1 hours) and propofol (four to six hours) 5, 6 . Finally, the sample size of the study was too small to confidently detect small, but potentially important, differences in their neurobiological effects on the brain.
Dexmedetomidine is a highly selective α2-adrenergic receptor agonist (2000 α 2 :1 α 1 ) and exerts its sedative effect by binding to transmembrane Gprotein-binding adrenoreceptors in the brain, spinal cord (α 2B , α 2C ) and periphery (α 2A ) tissues 7 . Its most appealing aspect as a sedative agent for neurosurgical patients relates to its ability to induce a sedative state, similar to physiological sleep, without respiratory depression by acting on α 2 receptors in the locus caeruleus [8] [9] [10] . As such, sedation interruption or substantial reduction in the dose of dexmedetomidine is not needed to assess neurological status and hence the potential risks of sedation interruption are avoided 11 . Furthermore, dexmedetomidine, either by itself or when used with hypothermia or lignocaine, also appears to have direct neuroprotective effects by reducing cortical apoptosis in animal models of cerebral ischaemia or subarachnoid haemorrhage [12] [13] [14] [15] [16] .
Editorial
Is dexmedetomidine an ideal sedative agent for neurosurgical patients? Anaesth Intensive Care 2012; 40: 927-928 Table 1 Potential advantages and disadvantages of dexmedetomidine as a sedative agent for neurosurgical patients
Advantages Disadvantages
1. Allows regular neurological assessments without reducing the dose or stopping the drug 2. Minimal respiratory depression 3. Analgesic effect and hence reduces opioid requirement 4. Reduces symptoms and signs of alcohol or drug withdrawal 5. Reduces intracranial pressure but maintain coupling between cerebral blood flow and cerebral metabolic rate 6. May have direct or synergistic neuroprotective effect with hypothermia, lignocaine or xenon (as shown in animal models of cerebral ischaemia) 7. Can be used to treat paroxysmal autonomic dystonia So far, clinical studies assessing the neuroprotective effect of dexmedetomidine are relatively limited 17 .
Although dexmedetomidine has many advantages over some traditional sedative agents (Table 1) , it also has some distinct disadvantages compared to benzodiazepines or propofol when used as a sedative agent for neurosurgical patients. These may include a significant risk of bradycardia when used with hypothermia 18 and a lack of anti-epileptic activity. Perhaps the time is ripe for an adequately powered phase IV randomised controlled trial to more fully assess the benefits and risks of dexmedetomidine as a sedative agent in critically ill neurosurgical patients.
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